Loading
Life sciences · Journal article
Pharmacological Reports · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Cancer therapy-related cognitive impairment (CRCI) is a frequent complication of cancer treatment. It involves multiple biological mechanisms: neuroinflammation, oxidative stress, mitochondrial dysfunction, impaired neurogenesis, and altered brain connectivity. Although these mechanisms have been extensively studied, evidence across cytotoxic chemotherapy, endocrine therapy, and targeted therapies is often presented separately. This review is the first of a two-part series addressing the mechanisms underlying CRCI and current and emerging therapeutic strategies for its prevention and management. It integrates available clinical and mechanistic research results across treatment classes, highlighting shared biological pathways, biomarkers, neuroimaging findings, and objective versus subjective cognitive outcomes to provide a comprehensive overview of CRCI.